Evidence map›Paper›PMID 41494158›Full record

ArticleACS infectious diseases2026

Diaryl-Aminoindazole with Extensive In Vitro Mycobactericidal Activity Dependent on Exposure to Reactive Nitrogen Species.

Thulasi Warrier, María Martínez-Hoyos, Esther Porras De Francisco, Anne J Lenaerts, Veronica Gruppo, Gregory T Robertson, Kelin Li, Jeffrey Aubé, Isabelle Bonnet, Xiuju Jiang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Thulasi WarrierDepartment of Microbiology and Immunology, Weill Cornell Medicine, New York, New York 100065, United States.
María Martínez-HoyosGlobal Health Medicines, R & D, GlaxoSmithKline, PTM Severo Ochoa 2, Tres Cantos 28760, Madrid Spain.
Esther Porras De FranciscoGlobal Health Medicines, R & D, GlaxoSmithKline, PTM Severo Ochoa 2, Tres Cantos 28760, Madrid Spain.
Anne J LenaertsMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado 80523, United States.
Veronica GruppoMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado 80523, United States.
Gregory T RobertsonMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado 80523, United States.
Kelin LiDivision of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Jeffrey AubéDivision of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Isabelle BonnetDepartment of Microbiology and Immunology, Weill Cornell Medicine, New York, New York 100065, United States.
Xiuju JiangDepartment of Microbiology and Immunology, Weill Cornell Medicine, New York, New York 100065, United States.
Véronique DartoisCenter for Discovery and Innovation, Hackensack Meridian School of Medicine, Nutley, New Jersey 07110, United States.ORCID 0000-0001-9470-5009
Brendan PrideauxCenter for Discovery and Innovation, Hackensack Meridian School of Medicine, Nutley, New Jersey 07110, United States.
Shashirekha MundhraDepartment of Microbiology and Immunology, Weill Cornell Medicine, New York, New York 100065, United States.
Carl F NathanDepartment of Microbiology and Immunology, Weill Cornell Medicine, New York, New York 100065, United States.ORCID 0000-0002-7744-8896
Alfonso Mendoza-LosanaGlobal Health Medicines, R & D, GlaxoSmithKline, PTM Severo Ochoa 2, Tres Cantos 28760, Madrid Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A bromoindazole was reported with the ability to rapidly and extensively kill

Indexed as

Antitubercular AgentsIndazolesMycobacterium abscessusMycobacterium tuberculosisReactive Nitrogen SpeciesAnimalsFemaleLungMiceMicrobial Sensitivity TestsMycobacterium aviumMycobacterium Infections, NontuberculousAntitubercular AgentsIndazolesReactive Nitrogen SpeciesMycobacterium abscessusMycobacterium aviumMycobacterium tuberculosisnitric oxide

Identifiers

PMID41494158
PMCPMC12910603

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.